Aliases & Classifications for Pancytopenia

MalaCards integrated aliases for Pancytopenia:

Name: Pancytopenia 12 29 54 6 44 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12450
ICD9CM 34 284.1
MeSH 44 D010198
NCIt 50 C34889
SNOMED-CT 67 127034005
ICD10 32 D61.81
UMLS 71 C0030312

Summaries for Pancytopenia

Disease Ontology : 12 An anemia that is characterized by a reduction in the number of red blood cells, white blood cells, and platelets.

MalaCards based summary : Pancytopenia is related to fanconi anemia, complementation group a and aplastic anemia. An important gene associated with Pancytopenia is DNAJC21 (DnaJ Heat Shock Protein Family (Hsp40) Member C21), and among its related pathways/superpathways are JAK-STAT signaling pathway and Cytokine production by Th17 cells in CF (Mouse model). The drugs Oprelvekin and Nandrolone decanoate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 74 Pancytopenia is a medical condition in which there is a reduction in the number of red and white blood... more...

Related Diseases for Pancytopenia

Diseases related to Pancytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 749)
# Related Disease Score Top Affiliating Genes
1 fanconi anemia, complementation group a 32.6 TP53 THPO FANCA DKC1 DHFR
2 aplastic anemia 31.7 TPMT TP53 THPO TERT MPL FOXP3
3 diamond-blackfan anemia 31.6 TP53 THPO TERT MPL FANCA EPO
4 hypersplenism 31.2 THPO FOXP3 EPO CSF3 CSF2
5 granulocytopenia 31.1 CSF3 CSF2 CP
6 neutropenia 31.1 TPMT TP53 THPO MPL EPO CSF3
7 hemoglobinuria 31.1 THPO EPO CSF3
8 thrombocytopenia 31.1 THPO TERT RUNX1 MPL MGMT FOXP3
9 paroxysmal nocturnal hemoglobinuria 31.0 THPO MPL EPO CSF3
10 myelofibrosis 31.0 TP53 THPO RUNX1 MPL EPO CSF3
11 myelodysplastic syndrome 30.9 TP53 THPO TERT SAMD9L RUNX1 MPL
12 acute leukemia 30.9 TPMT THPO RUNX1 MPL EPO CSF3
13 deficiency anemia 30.9 TTR THPO MPL FOXP3 FANCA EPO
14 leukemia, acute lymphoblastic 30.8 TPMT TP53 THPO RUNX1 MPL DHFR
15 dyskeratosis congenita 30.8 TP53 TERT FANCA EPO DNAJC21 DKC1
16 myeloid leukemia 30.8 TP53 TERT RUNX1 CSF3 CSF2
17 leukemia 30.7 TP53 THPO TERT RUNX1 MPL CSF2
18 iron deficiency anemia 30.7 THPO EPO CP
19 refractory anemia 30.7 RUNX1 MPL EPO CSF3
20 thrombocytosis 30.6 THPO MPL EPO CSF3 CSF2
21 polycythemia 30.5 THPO MPL EPO
22 pneumonia 30.5 TTR FOXP3 DHFR CSF3 CSF2
23 aspergillosis 30.5 CSF3 CSF2 CSF1
24 leukemia, acute myeloid 30.5 TP53 THPO TERT SAMD9L RUNX1 MPL
25 acute radiation syndrome 30.5 EPO CSF3
26 polycythemia vera 30.4 THPO MPL EPO CSF3 CSF2
27 shwachman-diamond syndrome 1 30.4 TP53 TERT FANCA DNAJC21 DKC1 CSF3
28 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.4 RUNX1 CSF1
29 malaria 30.4 TP53 FOXP3 EPO DHFR CSF3 CSF2
30 myelophthisic anemia 30.3 MPL EPO
31 peripheral nervous system disease 30.3 TTR TP53 EPO CSF3 CSF2
32 leukemia, chronic myeloid 30.3 TP53 THPO RUNX1 MPL EPO CSF3
33 splenic sequestration 30.3 THPO MPL EPO
34 acute promyelocytic leukemia 30.3 TP53 THPO TERT RUNX1 CSF3 CSF2
35 hemorrhagic disease 30.2 THPO RUNX1 MPL EPO CSF3
36 cyclic neutropenia 30.2 CSF3 CSF2 CSF1
37 granulosa cell tumor of the ovary 30.1 TP53 TERT CP
38 monocytic leukemia 30.1 RUNX1 CSF2 CSF1
39 myeloproliferative neoplasm 30.1 THPO RUNX1 MPL EPO CSF3 CSF2
40 malignant astrocytoma 30.1 TP53 TERT MGMT CSF3
41 childhood leukemia 30.1 TP53 RUNX1 DHFR CSF3
42 juvenile myelomonocytic leukemia 30.0 TP53 SAMD9L RUNX1 CSF2
43 acute monoblastic leukemia 30.0 EPO CSF2
44 severe congenital neutropenia 30.0 THPO RUNX1 CSF3 CSF2 CSF1
45 chronic myelomonocytic leukemia 29.9 TP53 RUNX1 MPL CSF3 CSF2 CSF1
46 hematologic cancer 29.8 THPO RUNX1 MPL CSF3 CSF2 CSF1
47 chronic mucocutaneous candidiasis 29.6 FOXP3 CSF2 CSF1
48 ataxia-pancytopenia syndrome 11.6
49 hoyeraal hreidarsson syndrome 11.3
50 fanconi anemia, complementation group c 11.2

Graphical network of the top 20 diseases related to Pancytopenia:



Diseases related to Pancytopenia

Symptoms & Phenotypes for Pancytopenia

MGI Mouse Phenotypes related to Pancytopenia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 CP CPT2 CSF1 CSF2 DHFR DKC1
2 hematopoietic system MP:0005397 10.36 CP CSF1 CSF2 CSF3 DHFR DKC1
3 cellular MP:0005384 10.29 CP CSF1 CSF2 DHFR DKC1 EPO
4 immune system MP:0005387 10.28 CP CPT2 CSF1 CSF2 CSF3 DHFR
5 cardiovascular system MP:0005385 10.26 CP CPT2 CSF1 CSF2 DHFR EPO
6 mortality/aging MP:0010768 10.16 CPT2 CSF1 CSF2 DHFR DKC1 DNAJC21
7 embryo MP:0005380 10.15 CPT2 CSF2 DHFR DKC1 EPO FANCA
8 endocrine/exocrine gland MP:0005379 10.13 CSF1 CSF2 DKC1 FANCA FOXP3 MGMT
9 integument MP:0010771 10.07 CSF1 CSF2 CSF3 DHFR DKC1 EPO
10 liver/biliary system MP:0005370 9.92 CP CSF1 DHFR EPO FOXP3 RUNX1
11 neoplasm MP:0002006 9.76 CSF2 DKC1 FANCA MGMT RUNX1 SAMD9L
12 no phenotypic analysis MP:0003012 9.5 CSF1 DKC1 FOXP3 MGMT RUNX1 TP53
13 respiratory system MP:0005388 9.36 CPT2 CSF1 CSF2 DKC1 EPO FOXP3

Drugs & Therapeutics for Pancytopenia

Drugs for Pancytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oprelvekin Approved, Investigational Phase 4 145941-26-0
2
Nandrolone decanoate Approved, Illicit Phase 3 360-70-3 9677
3
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 3 62-90-8 229455
4
Nandrolone Experimental, Investigational Phase 3 434-22-0 9904
5 Anabolic Agents Phase 3
6 Hormones Phase 3
7 Hormone Antagonists Phase 3
8 Androgens Phase 3
9
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
10
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
11 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
12
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
13
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
14
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
15
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
16
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
17
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
18
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
19
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
20
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
21
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
22
Mycophenolic acid Approved Phase 2 24280-93-1 446541
23
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
24
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
25
Mesna Approved, Investigational Phase 2 3375-50-6 598
26
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
27
alemtuzumab Approved, Investigational Phase 2 216503-57-0
28
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
29
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
30
Busulfan Approved, Investigational Phase 2 55-98-1 2478
31
Lenograstim Approved, Investigational Phase 2 135968-09-1
32
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
33
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
34
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
35 Adjuvants, Immunologic Phase 2
36 Antiparasitic Agents Phase 2
37 glucocorticoids Phase 2
38 Anthelmintics Phase 2
39 Mitogens Phase 2
40 Methylprednisolone Acetate Phase 2
41 Cyclosporins Phase 2
42 Antifungal Agents Phase 2
43 Dermatologic Agents Phase 2
44 Antiviral Agents Phase 1, Phase 2
45 Thymoglobulin Phase 2
46 Antilymphocyte Serum Phase 2
47 Anti-Infective Agents Phase 2
48 Antirheumatic Agents Phase 2
49 Calcineurin Inhibitors Phase 2
50 Antibiotics, Antitubercular Phase 2

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
2 Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases Unknown status NCT01019876 Phase 2, Phase 3 Fludarabine;Cyclophosphamide;Cyclophosphamide 40;Cyclophosphamide 30
3 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
4 Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Completed NCT00000597 Phase 3 antilymphocyte serum;nandrolone
5 Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
6 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
7 Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study Unknown status NCT02781155 Phase 1, Phase 2
8 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
9 Male Hormones for Telomere Related Diseases Unknown status NCT02055456 Phase 1, Phase 2 Nandrolone Decanoate
10 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2 Eltrombopag
11 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
12 A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy Completed NCT02404025 Phase 2 Eltrombopag;Rabbit ATG;CsA
13 A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
14 Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series Completed NCT00392951 Phase 1, Phase 2 sirolimus
15 Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
16 A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab Completed NCT00260689 Phase 2 Cyclosporine;Alemtuzumab
17 CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease Completed NCT01049854 Phase 2 Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
18 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2
19 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
20 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Completed NCT01193283 Phase 1, Phase 2 Cyclophosphamide;Cyclosporine
21 Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells Completed NCT02277639 Phase 2
22 Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
23 PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
24 Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure Recruiting NCT03500731 Phase 1, Phase 2 Rituximab;Alemtuzumab;Fludarabine;Thiotepa;G-CSF;Hydroxyurea
25 Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders Recruiting NCT04644016 Phase 2 Clofarabine;Fludarabine;Busulfan;Cyclosporine-A;Mycophenolate Mofetil
26 Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
27 A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation Recruiting NCT01962415 Phase 2 Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa
28 Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia Recruiting NCT04558736 Phase 2 Anti-Thymocyte Globulin (Rabbit);Fludarabine;Cyclophosphamide;Mesna;G-CSF
29 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells Recruiting NCT01174108 Phase 2
30 Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases Recruiting NCT03314974 Phase 2
31 Study of TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Hematopoietic Cell Transplantation From Haploidentical Donors in the Treatment of Non-Malignant Hematological Disorders in Children Recruiting NCT04356469 Phase 2
32 Phase II Trial of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Primary Immune Deficiencies, Immune Dysregulatory Syndromes, and Inherited Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide Recruiting NCT04232085 Phase 2 Alemtuzumab;Fludarabine;Melphalan;Cyclophosphamide;Tacrolimus;Mycophenolate Mofetil
33 Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT03622788 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
34 A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders Recruiting NCT03128996 Phase 1, Phase 2 RIC regimen;GVHD prophylaxis regimen
35 A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients Active, not recruiting NCT01328587 Phase 2 Eltrombopag
36 CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease Active, not recruiting NCT01966367 Phase 1, Phase 2
37 A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Active, not recruiting NCT02224872 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Mesna;Tacrolimus;Mycophenolic acid mofetil
38 A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies Active, not recruiting NCT01597219 Phase 2
39 A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia Active, not recruiting NCT02833805 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
40 Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases Active, not recruiting NCT02349906 Phase 2 Treosulfan;Busilvex
41 Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Suspended NCT01419704 Phase 1, Phase 2
42 Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders Terminated NCT01050439 Phase 2
43 Post Transplant CD34+ Selected Stem Cell Infusion to Augment Graft Function in Children With Primary Immunodeficiency Diseases and Bone Marrow Failure Syndromes Terminated NCT01856582 Phase 2
44 A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Terminated NCT01596699 Phase 2 Alemtuzumab;Busulfan;Fludarabine;Clofarabine
45 A Phase II Study Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients Terminated NCT00968864 Phase 2
46 Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients Completed NCT00001399 Phase 1 Transduced CD34+ Cells
47 A Phase I/II Trial of Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) in Patients Diagnosed With Acquired Aplastic Anemia Completed NCT00001398 Phase 1 Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
48 Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome Recruiting NCT03773393 Phase 1
49 A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases Active, not recruiting NCT02231710 Phase 1
50 A Phase I/II Study to Evaluate the Safety and Tolerability of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure Not yet recruiting NCT04211714 Phase 1

Search NIH Clinical Center for Pancytopenia

Cochrane evidence based reviews: pancytopenia

Genetic Tests for Pancytopenia

Genetic tests related to Pancytopenia:

# Genetic test Affiliating Genes
1 Pancytopenia 29

Anatomical Context for Pancytopenia

MalaCards organs/tissues related to Pancytopenia:

40
Bone Marrow, Myeloid, Bone, Kidney, Breast, T Cells, Skin

Publications for Pancytopenia

Articles related to Pancytopenia:

(show top 50) (show all 7160)
# Title Authors PMID Year
1
Perioperative management for a patient with chronic pancytopenia: a case of aplastic anemia with persistent neutropenia following preoperative administration of G-CSF. 61 54
20094735 2010
2
[Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen]. 61 54
20379108 2010
3
Massive ascites associated with all-trans retinoic acid treatment in therapy-related acute promyelocytic leukemia. 54 61
20190483 2010
4
Development of thrombopoietin receptor agonists for clinical use. 54 61
19630808 2009
5
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. 54 61
19037596 2009
6
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. 54 61
18541787 2008
7
Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. 61 54
18520612 2008
8
Acute colchicine intoxication in a child: a case report. 54 61
17505274 2007
9
[Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy]. 61 54
17313078 2007
10
Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. 54 61
17118765 2006
11
Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. 61 54
16995868 2006
12
MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. 54 61
16470591 2006
13
Thrombopoietin regulates differentiation of rhesus monkey embryonic stem cells to hematopoietic cells. 54 61
15958695 2005
14
[CD5- CD11c+ CD23- small lymphocytic lymphoma evolving from aplastic anemia]. 61 54
15387287 2004
15
[Spontaneous recovery from pancytopenia in a young female patient with paroxysmal nocturnal hemoglobinuria(PNH): changes in the GPI-anchor expression on peripheral blood cells]. 61 54
15103939 2004
16
Refractory chronic GVHD emerging after splenectomy in a marrow transplant recipient with accelerated phase CML. 54 61
12858207 2003
17
Co-administration of Flt-3 ligand counteracts the actions of thrombopoietin in myelosuppressed rhesus monkeys. 61 54
12694260 2003
18
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. 61 54
12477776 2003
19
Adult purpura fulminans associated with staphylococcal infection and administration of colony-stimulating factors. 54 61
12609794 2003
20
Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. 54 61
12454589 2002
21
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. 54 61
12172211 2002
22
Girl with combined cellular immunodeficiency, pancytopenia, malformations, deletion 11q23.3 --> qter, and trisomy 8q24.3 --> qter. 61 54
11920839 2002
23
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. 54 61
11895799 2002
24
[Successful combined therapy with ATG, cyclosporin and G-CSF for both liver dysfunction and bone marrow failure in hepatitis-associated aplastic anemia]. 54 61
11680980 2001
25
Colchicine induced toxicity and pancytopenia at usual doses and treatment with granulocyte colony-stimulating factor. 61 54
11361215 2001
26
Early onset methotrexate-induced pancytopenia and response to G-CSF: a report of two cases. 61 54
17039083 2001
27
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. 61 54
11133753 2001
28
One novel and two recurrent missense DKC1 mutations in patients with dyskeratosis congenita (DKC). 54 61
11491307 2001
29
Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. 61 54
11037857 2000
30
[Two cases of intravascular lymphomatosis diagnosed antemortem by transbronchial lung biopsy]. 61 54
10723949 2000
31
Serum thrombopoietin levels in thrombocytopenic and non-thrombocytopenic patients with human immunodeficiency virus (HIV-1) infection. 54 61
10530413 1999
32
Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. 54 61
10081639 1999
33
Recurrent hepatosplenomegaly and peripheral blood cytopenia, persistent Epstein-Barr virus infection and central nervous system manifestation in a patient with lymphadenopathy and low serum uric acid. 61 54
9745782 1998
34
Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. 61 54
9669693 1998
35
Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. 61 54
9541479 1998
36
T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. 61 54
9535034 1998
37
Crescentic glomerulonephritis accompanied by myeloperoxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7. 61 54
9469507 1998
38
Growth factor administration following autologous peripheral blood progenitor cell transplantation. 54 61
9373197 1997
39
Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. 54 61
9293906 1997
40
Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. 61 54
9207438 1997
41
Copper deficiency with pancytopenia due to enteral nutrition through jejunostomy. 61 54
16844585 1997
42
Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. 54 61
9092691 1997
43
Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. 54 61
9154449 1997
44
[Allopurinol induced pancytopenia in a patient with myeloproliferative disorder]. 54 61
9028164 1997
45
Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease. 54 61
8767533 1996
46
Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. 61 54
8701705 1996
47
[The Recormon (recombinant erythropoietin) treatment of a patient with pancytopenia of the blood and chronic viral hepatitis C]. 61 54
9019832 1996
48
Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. 61 54
8552605 1996
49
Trilineage response to granulocyte colony-stimulating factor administration in a patient with myelodysplastic syndrome. 54 61
7545637 1995
50
Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide. 61 54
7670408 1995

Variations for Pancytopenia

ClinVar genetic disease variations for Pancytopenia:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FOXP3 NM_014009.3(FOXP3):c.1190G>A (p.Arg397Gln) SNV Pathogenic 379222 rs1057520529 X:49107901-49107901 X:49251440-49251440
2 TTR NM_000371.4(TTR):c.424G>A (p.Val142Ile) SNV Pathogenic 13426 rs76992529 18:29178618-29178618 18:31598655-31598655
3 DNAJC21 NM_001012339.3(DNAJC21):c.544C>T (p.Arg182Ter) SNV Pathogenic 598950 rs771063992 5:34937536-34937536 5:34937431-34937431
4 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
5 CPT2 NM_000098.3(CPT2):c.149C>A (p.Pro50His) SNV Pathogenic 8954 rs28936375 1:53662764-53662764 1:53197092-53197092
6 RUNX1 NM_001754.4(RUNX1):c.502G>T (p.Gly168Ter) SNV Likely pathogenic 627081 rs1569078784 21:36252860-36252860 21:34880563-34880563
7 SOX3 NM_005634.2(SOX3):c.735_737dup (p.Ala248dup) Duplication Uncertain significance 95305 rs398124211 X:139586488-139586489 X:140504323-140504324

Expression for Pancytopenia

Search GEO for disease gene expression data for Pancytopenia.

Pathways for Pancytopenia

GO Terms for Pancytopenia

Biological processes related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.83 THPO EPO CSF3 CSF2 CSF1
2 replicative senescence GO:0090399 9.46 TP53 TERT
3 negative regulation of neuron death GO:1901215 9.43 EPO CSF3 CSF1
4 regulation of myeloid cell differentiation GO:0045637 9.4 RUNX1 CSF2
5 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.37 TP53 TERT
6 cytokine-mediated signaling pathway GO:0019221 9.35 TP53 MPL CSF3 CSF2 CSF1
7 response to salt stress GO:0009651 9.32 TP53 EPO
8 thrombopoietin-mediated signaling pathway GO:0038163 9.16 THPO MPL
9 regulation of regulatory T cell differentiation GO:0045589 8.8 RUNX1 FOXP3 FANCA

Molecular functions related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chaperone binding GO:0051087 9.43 TP53 TERT CP
2 growth factor activity GO:0008083 9.26 THPO CSF3 CSF2 CSF1
3 telomerase activity GO:0003720 9.16 TERT DKC1
4 cytokine activity GO:0005125 9.02 THPO EPO CSF3 CSF2 CSF1

Sources for Pancytopenia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....